Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences ... ( CRANBURY N.J. Sept. 17 /- Amicus ...)

Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference

Date:9/17/2008

CRANBURY, N.J., Sept. 17 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD), today announced that President and Chief Executive Officer John F. Crowley will make a presentation at the UBS Global Life Sciences Conference on Wednesday, September 24, 2008, at 10:30 a.m. EDT in New York.

An audio webcast of the presentation will be available at the Amicus Web site at http://www.amicustherapeutics.com. Participants should allow approximately five to ten minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the webcast. An audio replay of the webcast will also be available on the Company's Web site for 30 days until October 24, 2008.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease.

FOLD-G

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Post Your Comments:

(Date:12/3/2009)... Shire plc (LSE: SHP, Nas...cal company, today announced a voluntary recall of...lot of the Attention-Deficit/Hyperactivity Disorde...his action because some Daytrana patches do not me...er removal specification, and as a result, patient...

(Date:12/3/2009)...c. 3 Caliper Life Scienc...ools and services for drug discovery and life scie...oftware for IVIS® in vivo imaging systems. Li...er IVIS systems currently installed in laboratorie...ectral unmixing tools to enhance fluorescent sensi...

(Date:12/2/2009)...c. 2 Spectrum Blue Steel is emergi...anies on the planet. Through the efforts of True G...t and Recycling Specialist Leroy Johnston, who has... stated that Spectrum Blue Steel is light years ah...acular earnings because of the bi products recover...

(Date:12/2/2009)... Reportlinker.com announces that a...talogue: ,, Drug Discovery Technologies - A Gl...,, http://www.reportlinker.com/p0164246/Drug-D...Trends--Opportunities.html ,, Drug discovery h... pharmaceutical company,s business strategy. There...

[0] Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced [0] Caliper Life Sciences Launches Living Image(R) 4.0 Software [0] Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators [0] Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities

... is Cepheid,s Second FDA Cleared Diagnostic Test i...n Twenty-Four Hours Over Conventional ...t. 1 Cepheid (Nasdaq:,CPHD) today announced it ha...inistration (FDA) to market its Xpert(TM) MRSA/SA ...rt(R) System, for the detection of,Methicillin-res...

... October 1 , - "Expert Consult" Title Regularly I... Always Current, Elsevier, the leading publisher ... publication of the 40th edition of the most famou...y: The Anatomical Basis of Clinical,Practice ( htt...0443066849 ),in September 2008., In celebration o...

...if., Oct. 1 Lumiphore, Inc., a,biotechnology lead...nt,metal-lanthanide technology for use in high-val...xclusive agreement with Biophor Diagnostics, Inc.,...ts in diagnostic tests,for drugs of abuse., Under...usive worldwide,rights to Lumi4(TM) technology in ...

Other Biology Technology:Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures 2 Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures 3 Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures 4 Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures 5 New 40th Edition of Gray's Anatomy Celebrates 150 Years as the World's Preeminent Anatomical Reference 2 New 40th Edition of Gray's Anatomy Celebrates 150 Years as the World's Preeminent Anatomical Reference 3 Lumiphore Partners with Biophor Diagnostics, Inc. to Develop Tests for Drugs of Abuse; Appoints Ibis Biosciences Founder David J. Ecker to Board 2

Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures New 40th Edition of Gray's Anatomy Celebrates 150 Years as the World's Preeminent Anatomical Reference Lumiphore Partners with Biophor Diagnostics, Inc. to Develop Tests for Drugs of Abuse; Appoints Ibis Biosciences Founder David J. Ecker to Board

(Date:12/2/2009)...ntain forest,s woodland herb population has shown ...ories recover from logging, according to Purdue Un...rtions of the forest nearly 80 years ago, the dist...t floor was similar to that of undisturbed areas. ...orestry and natural resources, said that contrasts...

(Date:12/2/2009)...nter researchers have figured out how stem cells i...able to resist radiation therapy. And using a drug...cancer stem cells, they were able to kill many mor...riment. , The work builds off earlier research ...ects of radiation much better than other cancer ce...

(Date:12/2/2009)...roduct called moist snuff placed between lip and ...obacco industry to change manufacturing practices ...udy is published online in ACS, monthly journal C...his category of tobacco products contains surprisi...ng substances. Called polycyclic aromatic hydrocar...

Breaking Biology News(10 mins):Study finds logging effects vary based on a forest's history, climate 2 Discovery makes brain tumor cells more responsive to radiation 2 INV102 Asthma Product Discussed at the European Respiratory Society 14206 1 INV102 Asthma Product Discussed at the European Respiratory Society 14206 2 ESMO recognizes centers of excellence in palliative care for cancer patients 57956 1 ESMO recognizes centers of excellence in palliative care for cancer patients 57956 2 NKTR 102 Shows Encouraging Anti Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplin 5029 1 NKTR 102 Shows Encouraging Anti Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplin 5029 2 NKTR 102 Shows Encouraging Anti Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplin 5029 3 NKTR 102 Shows Encouraging Anti Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplin 5029 4 NKTR 102 Shows Encouraging Anti Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplin 5029 5

[0] Study finds logging effects vary based on a forest's history, climate [0] Discovery makes brain tumor cells more responsive to radiation [0] Smokeless tobacco called 'moist snuff' is contaminated with harmful substances

..., Nitrogen pollution from agriculture and fossil ... in the UK. A new European study is starting to sh... current policies to protect ecosystems may need a...in 2004, her findings were so significant they wer...elected as contributing to one of the top ten scie...

..., Athens, Ga. For the estimated millions of AIDS...oping resistance to currently available medicines,... may offer a new treatment option by targeting a p... responsible for the devastating disease. , Appr...ectious viral disease known as HIV-AIDS. Although ...

..., WALNUT CREEK, -The genome analysis of a tiny gr...uniquely associated with carbon dioxide capture an...es revealed in the study are those that encode the...le that houses the photosynthetic apparatus, the c...ght to chemical energy. The genome also provides ...

Other Biology News:Nitrogen -- the silent species eliminator 2 Nitrogen -- the silent species eliminator 3 New class of drug offers hope to treatment-resistant AIDS patients 2 New class of drug offers hope to treatment-resistant AIDS patients 3 Green alga genome project catalogs carbon capture machinery 2 Green alga genome project catalogs carbon capture machinery 3

Nitrogen -- the silent species eliminator New class of drug offers hope to treatment-resistant AIDS patients Green alga genome project catalogs carbon capture machinery

Mouse Anti-Keap1 Monoclonal Antibody, Unconjugated, Clone 333116 from R&D Systems

Anti-Myelin Basic Protein (MBP), aa 129-138 Monoclonal Antibody, Unconjugated, Clone clone 1 from CHEMICON

Normal Guinea Pig Serum from Equitech-Bio

ELF 97 Cytological Labeling Kit *with streptavidin alkaline phosphatase conjugate* *50 assays* from Molecular Probes (Invitrogen)

Biology Products:

Mouse Anti-Keap1 Monoclonal Antibody, Unconjugated, Clone 333116 from R&D Systems Anti-Myelin Basic Protein (MBP), aa 129-138 Monoclonal Antibody, Unconjugated, Clone clone 1 from CHEMICON Normal Guinea Pig Serum from Equitech-Bio ELF 97 Cytological Labeling Kit *with streptavidin alkaline phosphatase conjugate* *50 assays* from Molecular Probes (Invitrogen)

Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences ...( CRANBURY N.J. Sept. 17 /- Amicus ...)